drugset
drugset / Trial / NCT03111485

Effect of Long-acting Levodopa on Obstructive Sleep Apnea in Parkinson's Disease

NCT03111485 ↗

Phase 4 Completed 36 enrolled McGill University Health Centre/Research Institute of the McGill University Health Centre Weston Brain Institute · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

This trial will assess whether long-acting levodopa taken at night improves obstructive sleep apnea (OSA) in patients with Parkinson's disease (PD), as compared with placebo.

Timeline

Start
2017-05-24
Primary completion
2022-10-28
Completion
2022-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 50 mg —
Subject Levodopa Small molecule 250 mg —

Indications

Parkinson disease obstructive sleep apnea syndrome